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Background: We compared PCV7 serological response and protection against carriage in infants receiving
3 doses (2, 4, 6 months; 3+0 schedule) to those receiving a booster (12 months; 3+1).
Methods: A prospective, randomized controlled study, conducted between 2005 and 2008, before PCVs
were implemented in Israel. Healthy infants were randomized 1:1:1 to receive 3+1, 3+0 and 0+2 (control
group; 12, 18 months doses). Nasopharyngeal/oropharyngeal swabs were obtained at all visits. Serum
serotype-specific IgG concentrations and opsonic activities (OPA) were measured at 2, 7, 13 and 19
months. This study was registered with Current Controlled Trials, Ltd. ISRCTN28445844.
Results: Overall, 544 infants were enrolled: 3+1 (n = 178), 3+0 (n = 178) and 0+2 (n = 188).
Post-priming (7 months), antibody concentrations were similar in both groups, except for serotype 18C
(higher in 3+0). Post-booster (13, 19 months), ELISA and OPA levels were significantly higher in 3+1 than
in 3+0 group.
Nasopharyngeal/oropharyngeal cultures were positive for Streptococcus pneumoniae in 2673 (54.3%)
visits. Acquisition rates (vaccine and non-vaccine serotypes) were similar for 3+1 and 3+0 groups at 7–
30 months and for 0+2 group at 19–30 months.
Conclusions: PCV7 booster after 3 priming doses increased substantially IgG concentrations but did not
further reduced vaccine-serotype nasopharyngeal acquisition, suggesting that protection from pneumo-
coccal carriage does not depend primarily on serum IgG.
 2018 Elsevier Ltd. All rights reserved.1. Introduction However, considerations regarding the high cost of PCVs and theThe 7-valent CRM197 pneumococcal conjugate vaccine (PCV7)
was licensed in the US in the early 2000s for use as 3 infant doses
and a booster in second year of life (3+1 schedule) [1]. Subse-
quently, many countries introduced pneumococcal conjugate vac-
cines (PCVs) into their national immunization program (NIP) [2,3].growing number of injections in infant vaccination regimens led
many countries to choose different (reduced) schedules with no
toddler dose (3+0) and 2 infant doses with a toddler booster dose
(2+1) [4].
Schedules with a lower number of doses often elicit lower
immune response compared to the original 3+1 schedule [5–11].
Furthermore, a higher nasopharyngeal carriage rate with decreas-
ing number of PCV doses in infants was observed in several studies
[6,12,13]. However, the clinical consequences of the immunologic
differences are not entirely clear and are subject to debate
[10,11]. Systematic reviews support a 3+0 schedule, which in var-
ious studies was typically used in infants at 6, 10, and 14 weeks or
2, 4, and 6 months schedules (the latter was often studied com-
pared with a booster toddler dose as a 3+1 schedule) [10,14].
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types included in PCV7 and serotype 6A (7VT+6A) plays an impor-
tant role in the success of immunization programs, by reducing
transmission to susceptible subjects, resulting in indirect (herd)
protection [15,16]. In the US, a near total elimination of 7VT+6A
was observed in all ages in the PCV7 era [17]. Several studies have
shown that a 3+0 regimen was also associated with carriage reduc-
tion [8,13,18–20]. Furthermore, after the introduction of the 3+0
PCV7 regimen to the NIP in Australia, indirect protection was
demonstrated [21]. However, these reports do not enable compar-
ison of the 3+0 and 3+1 regimens, and to determine whether the 3
+0 regimen is equivalent to the 3+1 regimen in its ability to induce
and maintain reduction in 7VT+6A pneumococcal serotypes in the
community. Furthermore, a recent study from Australia suggested
that after 13-valent conjugated vaccine (PCV13) introduction with
the 3+0 regimen, a lower herd protection than expected was
observed, prompting a change to a 3+1 regimen [22].
We conducted a prospective randomized controlled study prior
to PCV7 implementation in Israel to examine the added value of
the booster dose in protecting against carriage in toddlers who
had received 3 infancy doses by comparing the effect of the 3+0
and 3+1 responses on acquisition and prevalence of pneumococcal
carriage in infants and toddlers. We also included in this group of
children those who were not vaccinated in the first year of life, but
received a 2-dose regimen at 12 and 18 months (0+2), to assess the
toddler-only schedule on carriage, as this schedule only protects
directly against infections caused by vaccine-serotypes in toddlers
and does not protect directly against infections in infants.2. Methods
2.1. Setting
Two ethnic groups whose socioeconomic conditions and life-
styles differ inhabit Southern Israel (the Negev region): the Jewish
and the Bedouin populations. The Bedouin population, formerly
desert nomads, in transition to a western lifestyle, is characterized
by overcrowding, lower levels of education, lower income and lar-
ger family size than the Jewish population [23]. Pneumococcal
nasopharyngeal carriage is usually higher among Bedouin infants
than among Jewish infants [24]. Approximately 95% of all routine
immunizations in Israel are given in public sector Mother-and-
Child Health Centers (MCHCs). In the present study, we selected
7 MCHCs, 4 serving the Jewish population and 3 serving the Bed-
ouin population (yearly birth cohorts of 1400 and 1700,
respectively).
PCV7 was licensed in Israel in 2006 and became publicly avail-
able in 2007. However, in southern Israel, only <10% and <25% of
children received the vaccine before 2008 and between 2008 and
mid-2009, respectively. In July 2009, PCV7 was implemented in
the Israeli NIP.2.2. Participants
Healthy infants were enrolled at the age of 2 months (±3
weeks). Exclusion criteria were: prematurity (<35 weeks); fever
(>38 C); congenital abnormalities; metabolic disorders; coagula-
tion disorders; use of immune-modifying drugs; allergy to 1 vac-
cine constituents; hypotonic-hyporesponsiveness or persistent
inconsolable crying after any prior vaccine; and HIV infection.
The study was approved by the Ethics Committees of the Soroka
University Medical Center, Maccabi Health Services and the Min-
istry of Health and was registered with Current Controlled Trials,
Ltd. ISRCTN28445844.2.3. Study design
This open-label study was initiated in August 2005. Enrollment
was conducted through March 2008, and the last follow-up visit
was in March 2009, before the implementation of PCV7 in the
Israeli NIP. We invited 3100 eligible infants who belonged to
the study MCHCs to take part in the study. The parents of 1141
infants were willing to consider participation in the study, and
eventually 733 infants were enrolled [12]. After an informed con-
sent was obtained, subjects were randomized 1:1:1:1 to receive
3 PCV7 doses at 2, 4, 6 months and a 4th toddler dose at 12
months, (3+1; n = 178); 3 PCV7 doses at 2, 4, 6 months with no
additional toddler doses (3+0; n = 178); and no dose during infancy
but 2 doses in the second year at 12, 18 months (control group, 0
+2; n = 188) (Fig. 1) [12]. The third group, originally studied as a
‘‘catch-up” schedule for the purpose of PCV7 national immuniza-
tion plan introduction [12] was chosen as a control group for both
the 3+1 and 3+0 groups, since they did not receive any PCV7 dose
during their first year of life. An additional 189 subjects were
enrolled to a 2+1 arm (presented in a previous article) [12].
The study vaccine was PrevenarTM (Wyeth Vaccines; Collegeville,
PA, USA) containing 7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F)
individually conjugated to CRM197; lots used were no. A94431D,
B08636C, 808672K and C659732), All infants received concomitant
vaccines.
Blood (2–4 mL) was drawn at ages 2, 7, 13 and 19 months,
transferred refrigerated within 8 h to the laboratory, separated
within 24 h and kept at 70 C until processed. In group 0+2, sub-
jects were randomized (1:1) to give blood samples at 2 months or
at 7 months of age, but all gave blood at 13 and 19 months.
Nasopharyngeal and oropharyngeal swabs were obtained at
each visit using transport swabs (nasopharyngeal – MW173 Amies
transport medium, Transwab, Medical Wire and Equipment, Pot-
ley, UK; oropharyngeal – Culture-Swab Transport System, Venturi
Transystem, Copan Innovation, Italy). The swabs were kept at
room temperature and processed within 16 h. Results of the
oropharyngeal swabs for positive pneumococcal culture were used
only if the nasopharyngeal swabs were culture-negative. Pneumo-
coccal identification and serotyping were performed as previously
described [25].2.4. Serologic assays
Serum serotype-specific pneumococcal anti-capsular IgG con-
centrations for PCV7 serotypes (4, 6A, 6B, 9V, 14, 18C, 19F and 23F)
weremeasured using ELISA at the Department of Applied Immunol-
ogy & Endocrinology, Kinder und Jugendklinik Universitatsklinikum
Erlangen, Germany, after double absorption with C-polysaccharide
and pneumococcal serotype 22F polysaccharide [5,26–28].
The opsonic activities of anti-pneumococcal antibodies were
measured against PCV7 serotypes by a fourfold multiplexed
opsonophagocytosis assay (MOPA) as previously described [29],
with minor modifications [30].
Serum samples from which enough serum volume was avail-
able (n = 281) were submitted also to MOPA assay (in addition to
ELISA assay). For those samples, ELISA GMCs were compared to
MOPA GMTs. Since serotype 6A antigen is not a part of PCV7, ser-
otype 6A MOPA was compared to serotype 6B ELISA antibodies.2.5. Data and statistical analysis
Data were analyzed with SPSS 18.0 software for Windows (Chi-
cago, IL, USA). Contingency table analyses were performed using
v2 test or Fisher’s exact test. Continuous variables were analyzed
using the t-test or ANOVA procedures. Correction for ethnicity
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Fig. 1. Study design. NP, nasopharyngeal; OP, oropharyngeal. At ages 2, 4, 6 and 12 months – diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b and
inactivated poliovirus vaccine (DTaP-IPV-PRPT, GlaxoSmithKline Biologicals, Rixensart, Belgium); at ages 12 months – measles, mumps and rubella vaccine (MMR;
GlaxoSmithKline Biologicals Rixensart, Belgium). Hepatitis B vaccine (HBV) was given outside the study visits at ages 0, 1, and 7 months. Hepatitis A vaccine (HAV) was given
outside the study visits at ages 18, and 24 months.
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value <.05 was considered significant.
For the post-primary series, the proportion of subjects with
serotype-specific IgGconcentrations0.35and>1.0 mg/mLwere cal-
culated. For ages 13 and 19 months the proportion of subjects with
concentration >1.0 and >5.0 mg/mL were calculated. The latter was
associated in previous publications with protection against carriage
[31,32]. Additional comparisons between groups were conducted
using log10-transformed geometric mean concentrations (GMCs).544 su
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Fig. 2. Flow diagram for the study groups. NP, nasopharyngeal; OP, oropharyngeal. The 0
SD = Standard Deviation.Since protection against serotype 6A may be obtained through
antibodies elicited by serotype 6B antigen [33], we combined ser-
otype 6A in the analysis with 7VT.
In a previous study [5], we demonstrated that although Bedouin
infants had higher maternally-derived serotype-specific serum IgG
than the Jewish infants for all serotypes, after the infant immuniza-
tion series, no significant difference between the 2 ethnic groups
was observed. Nevertheless, all serology results were adjusted for
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Table 1
Serum serotype-specific pneumococcal anticapsular IgG GMCs (mg/mL) and percent of subjects achieving serum concentrations 0.35, >1.0 and >5.0 mg/mL at 7, 13 and 19 months of age.
Serotype 7 months 13 months 19 months
3+1
n = 145
3+0
n = 157
0+2
n = 86
P 3+1
n = 145
3+0
n = 152
0+2
n = 156
P 3+1
n = 146
3+0
n = 139
0+2
n = 141
P*
4 GMC (95% CI) 1.9
(1.6;2.3)
2.0
(1.7;2.2)
0.0
(0.0;0.0)
b2,c2 4.0
(3.4;4.7)
0.3
(0.3;0.4)
2.5
(2.1;3.1)
a2,b2,c2 0.4
(0.4;0.5)
0.1
(0.1;0.2)
4.4
(3.7;5.3)
a2,b2,c2
% 0.35 mg/mL 98.6 98.1 2.3 b2,c2 ND ND ND ND ND ND ND ND
% >1.0 mg/mL 77.9 79.6 1.2 b2,c2 91.0 9.9 78.1 a2,b1,c2 81.4 46.8 100 a2,b2,c1
% >5.0 mg/mL ND ND ND ND 42.8 0.0 30.1 a2,b1,c2 19.9 10.8 89.4 a1,b2,c2
6B GMC (95% CI) 2.3
(1.8;3.0)
1.9
(1.4;2.4)
0.1
(0.1;0.1)
b2,c2 11.0
(8.8;13.8)
0.8
(0.6;1.0)
0.4
(0.3;0.5)
a2,b2,c2 2.0
(1.6;2.4)
0.8
(0.6;0.9)
2.9
(2.3;3.7)
a2,b1,c2
% 0.35 mg/mL 89.7 83.4 8.1 b2,c2 ND ND ND ND ND ND ND ND
% >1.0 mg/mL 72.9 70.7 1.2 b2,c2 93.1 40.8 25.2 a2,b2,c1 23.3 5.0 87.2 a2,b2,c2
% >5.0 mg/mL ND ND ND ND 79.3 9.2 2.6 a2,b2,c1 0.7 0.7 15.7 b2,c2
9 V GMC (95% CI) 1.5
(1.2;1.7)
1.4
(1.3;1.6)
0.1
(0.1;0.1)
b2,c2 3.5
(3.0;4.0)
0.5
(0.4;0.5)
2.0
(1.7;2.4)
a2,b2,c2 0.7
(0.6;0.8)
0.3
(0.3;0.4)
3.6
(3.0;4.2)
a2,b2,c2
% 0.35 mg/mL 96.6 96.2 4.7 b2,c2 ND ND ND ND ND ND ND ND
% >1.0 mg/mL 64.1 66.0 2.3 b2,c2 92.4 16.4 78.7 a2,b1,c2 43.8 30.2 85.8 a1,b2,c2
% >5.0 mg/mL ND ND ND ND 33.1 0.0 18.1 a2,b1,c2 14.4 10.8 55.3 b2,c2
14 GMC (95% CI) 5.2
(4.2;6.5)
5.0
(4.2;6.1)
0.1
(0.0;0.1)
b2,c2 12.9
(11.0;15.2)
1.4
(1.1;1.7)
2.1
(1.7;2.6)
a2,b2,c1 2.4
(2.0;2.8)
0.9
(0.7;1.1)
15.4
(13.2;17.9)
a2,b2,c2
% 0.35 mg/mL 93.8 95.5 20.9 b2,c2 ND ND ND ND ND ND ND ND
% >1.0 mg/mL 88.3 87.3 4.7 b2,c2 98.6 61.2 73.1 a2,b2,c1 46.9 8.6 80.7 a2,b2,c2
% >5.0 mg/mL ND ND ND ND 84.1 11.2 23.7 a2,b2,c1 6.2 0.7 27.7 a1,b2,c2
18C GMC (95% CI) 1.5
(1.3;1.8)
1.7
(1.5;1.9)
0.0
(0.0;0.0)
b2,c2 3.7
(3.2;4.3)
0.3
(0.3;0.4)
1.9
(1.6;2.3)
a2,b2,c2 0.5
(0.4;0.6)
0.2
(0.2;0.2)
2.3
(2.0;2.7)
a2,b2,c2
% 0.35 mg/mL 93.8 98.7 1.2 a1,b2,c2 ND ND ND ND ND ND ND ND
% >1.0 mg/mL 72.7 73.5 1.2 b2,c2 91.0 8.6 75.0 a2,b2,c2 15.8 1.4 91.4 a2,b2,c2
% >5.0 mg/mL ND ND ND ND 38.6 0.7 18.6 a2,b2,c2 2.7 0.7 52.5 b2,c2
19F GMC (95% CI) 1.8
(1.5;2.2)
2.1
(1.8;2.5)
0.0
(0.0;0.0)
b2,c2 4.1
(3.4;4.9)
0.5
(0.4;0.7)
0.4
(0.4;0.5)
a2,b2 1.0
(0.8;1.3)
0.6
(0.5;0.8)
5.0
(3.9;6.3)
a1,b2,c2
% 0.35 mg/mL 91 94.9 1.2 b2,c2 ND ND ND ND ND ND ND ND
% >1.0 mg/mL 74.5 78.3 1.2 b2,c2 89.0 23.0 26.9 a2,b2 73.1 37.0 75.2 a2,c2
% >5.0 mg/mL ND ND ND ND 46.2 8.6 3.2 a2,b2,c1 19.9 7.2 39.7 a1,b2,c2
23F GMC (95% CI) 1.3
(1.0;1.5)
1.0
(0.9;1.3)
0.1
(0.0;0.1)
b2,c2 5.6
(4.7;6.7)
0.4
(0.3;0.5)
0.6
(0.5;0.7)
a2,b2,c1 0.9
(0.7;1.1)
0.3
(0.2;0.3)
2.8
(2.2;3.4)
a2,b2,c2
% 0.35 mg/mL 88.3 82.2 4.7 b2,c2 ND ND ND ND ND ND ND ND
% >1.0 mg/mL 57.6 51.9 2.3 b2,c2 95.9 19.7 32.3 a2,b2,c1 29.5 8.6 91.4 a2,b2,c2
% >5.0 mg/mL ND ND ND ND 54.9 1.3 5.1 a2,b2 2.7 1.4 34.0 b2,c2
a, 3+1 vs 3+0 group: a1, .001  P < .05; a2, P < .001.
b, 3+1 vs 0+2 group: b1, .001  P < .05; b2, P < .001.
c, 3+0 vs 0+2 group: c1, .001  P < .05; c2, P < .001.
ND = Not done.
* P value adjusted for ethnic group.
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2778 R. Dagan et al. / Vaccine 36 (2018) 2774–2782influence the association between IgG concentrations and preven-
tion of carriage despite differences in carriage rates [34].
New pneumococcal acquisition was defined as acquisition of a
serotype not seen at any previous visit. New acquisitions were cal-
culated from 7 months of age (one month following complete
infant series) onwards. Cumulative incidences were calculated by
adding the incidence of a certain point (adjusted for ethnicity) to
all previous rates within the same group. All acquisitions and
prevalence rates are expressed per 100 children.3. Results
Overall, 3100 eligible infants were invited to take part in the
study. The parents of 1141 were willing to consider participation
in the study, and 544 agreed to be enrolled: 3+1 (n = 178), 3+0
(n = 178) and 0+2 (n = 188) (Fig. 2). At all visits, the mean age
was similar in all groups. Bedouin infants constituted 50% and
females constituted 48% of subjects, with no significant differences
in these distributions between the 3+1, 3+0 and 0+2 groups.3.1. Immunogenicity
At 7 months of age, no significant differences in immunogenic-
ity between the 3+0 and 3+1 groups were observed, except for ser-
otype 18C, with a higher proportion of infants with antibody
concentrations 0.35 lg/ml in the 3+0 group (Table 1). For all ser-
otypes, the antibody concentrations were higher among both 3+1
and 3+0 groups compared to the 0+2 group.0.01
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higher in the 3+1 than in the 3+0 group for all serotypes. The 0
+2 group (after 1 dose at 12 months) had higher antibody concen-
trations than the 3+0 group for all serotypes, except 19F and 6B,
and lower antibody concentrations than the 3+1 group for all ser-
otypes. At age 19 months, one month after the second PCV7 dose
for group 0+2, the antibody concentrations in the 0+2 group were
higher for all serotypes compared to both 3+1 and 3+0 groups. The
concentrations in the 3+1 group were all significantly higher than
those in the 3+0 group.
Trends for ELISA GMCs paralleled those of MOPA GMTs for each
serotype and study age group (Fig. 3).
3.2. Nasopharyngeal/oropharyngeal new acquisition rates
Overall, nasopharyngeal/oropharyngeal (NP/OP) cultures sam-
ples were obtained in 4925 visits: 1616, 1628 and 1681 for the 3
+1, 3+0, and 0+2 groups, respectively (Fig. 2). Cultures were posi-
tive for S. pneumoniae in 2673 (54.3%) visits; of these, 0.6% were
positive from the OP sample only. A total of 496 (10.1%) new acqui-
sitions of 7VT+6A were observed: 6A (123, 2.5%), 19F (112, 2.4%)),
6B (78, 1.6%), 23F (77, 1.6%), 14 (55, 1.1%), 18C (25, 0.5%), 9V (20,
0.4%) and 4 (6, 0.1%). Serotypes 6A and 6B constituted together
40.5% of all new acquisitions.
3.2.1. Comparison between the 3+1, the 3+0 and the 0+2 groups
Acquisition of 7VT+6A (combined) was similar for groups 3+1
and 3+0 at all ages from 7 to 30 months, with no significant differ-
ences in any of the age points (Fig. 4A. P-values in Fig. 4 reflect the1
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Fig. 4. Comparison of cumulative incidence (per 100 children) of new pneumococcal NP/OP acquisitions between the 3+1 and 3+0 groups. These 2 groups were in turn
compared to the 0+2 groups, who received no PCV7 during the first year of life, but received 2 doses in the second year of life. (A) PCV7 serotypes (including serotype 6A). (B)
Serotype 6B separately. (C) Serotype 6A separately. (D) Non-PCV7 serotypes (excluding serotype 6A). All P-values were adjusted for ethnic groups (Jewish vs. Bedouin
children). a P-values between the 3+1 and 3+0 groups. b P-values between the 3+1 and 0+2 groups. c P-value between the 3+0 and 0+2 groups. The denominators used for the
calculation of the incidence rates presented in Fig. 4 are detailed in Fig. 2.
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incidences.). Both groups differed significantly from the 0+2 group
at ages 7–12 months (a period during which no dose was adminis-
tered to the 0+2 group), and ages 13–18 months (after 1 dose at 12
months among the 0+2 group). However, at ages 19–30 months
(after group 0+2 received 2 PCV doses), no significant differences
between the 0+2 groups and the 3+1 or 3+0 group were observed.
Several differences were observed for serotypes 6B separately and
6A separately (Fig. 4B and C). These include higher cumulative inci-
dences of serotype 6B in the 0+2 group compared with the 3+0
group at ages 7–12 months and the 3+1 and 3+0 groups at ages
13–18 months. Similarly, for serotype 6A, higher cumulative inci-
dences in the 0+2 group were observed compared with the 3+1
and 3+0 groups at ages 13–18 months. For non 7VT+6A serotypes,
no difference was observed between groups 3+1 and 3+0, but for
the 3+0 group acquisitions of non VT7 at ages 7–18 months was
significantly higher than the group 0+2 (Fig. 4D).
3.3. Prevalence rates of nasopharyngeal/oropharyngeal carriage
At any time point, and for all comparisons, no significant
differences between groups 3+1 and 3+0 in the mean carriageprevalence were observed (Fig. 5). However, for all V7T+6A com-
bined, and serotypes 6B and 6A separately, the mean carriage
prevalence in groups 3+0 and 3+1 was generally lower than that
in the 0+2 group. This difference was statistically significant at ages
7+12 and 13+8 months for 7VT+6A combined; all ages for serotype
6B; and age 13+18 months for serotype 6A.
For non-VT+6A, the mean carriage prevalence was significantly
higher in the 3+1 and 3+0 groups than in the 0+2 group at ages 7
+12 and 13+18 months. No significant differences were observed
for overall pneumococcal carriage prevalence between all groups.4. Discussion
In the current study, when PCV7 was administered to infants at
a 3-dose schedule with a 2-month interval (2, 4 and 6 months of
age), adding a further dose at 12 months of age markedly and sig-
nificantly boosted serotype-specific anticapsular IgG responses to
all 7 serotypes and OPA titers to all measured serotypes, resulting
in higher concentrations than without a booster for at least 6
months. However, paradoxically, no significant added benefit was
observed in term of both nasopharyngeal acquisition and preva-
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age. To the best of our knowledge, this is the only study that com-
pared the efficacy of 3+0 vs. 3+1 regimens on carriage with a rela-
tively long follow-up (age 2.5 years).
These findings are unique for several reasons. First, while 3+0
PCV schedules were studied in several countries worldwide and
both efficacy/effectiveness against both invasive pneumococcal
disease [22] and nasopharyngeal carriage [35], and impact on these
outcomes were shown, none of these studies were compared head-
to-head to the 3+1 regimen. To our knowledge, this is the first
study that compared 3+1 and 3+0 schedules within a comparative
randomized trial. Furthermore, the study was conducted in Israel
during a period when PCVs were not part of the NIP. This is of cru-
cial importance, since without such a head-to-head study, it is dif-
ficult to assess the real difference in efficacy of the different
schedules against nasopharyngeal carriage. Second, our findings
are reassuring and suggest that reduced schedules may impact
equally both direct and indirect protection through reduced VT7
spread. Reduced schedules are indeed desirable for several reasons,
including the high cost of PCVs and to limit the growing number of
injections in infant vaccination. Third, while a higher nasopharyn-
geal carriage rate with decreasing number of PCV doses in infants
was observed in several studies [8,12,13], our results demonstrate
that the number of doses may play a smaller role than previously
thought in reducing carriage, at least in a schedule with a 2-month interval between doses. Whether similar results can be
obtained with a shorter interval between doses (i.e. the 6, 10, 14
week interval used in developed countries), is not clear.
The lack of direct correlation between the post-booster serum
antibody and carriage acquisition and prevalence is somewhat sur-
prising. The following can be a plausible explanation. Correlation
between serotype-specific IgG concentrations and nasopharyngeal
acquisition of pneumococcus post infant 3-dose primary series was
clearly demonstrated [33,34]. It may be speculated that high blood
IgG concentration is not, by itself, sufficient for the prevention of
carriage acquisition. Protection against carriage may require an
additional stimulation of the immune system, building a higher
number of memory B-cells. This hypothesis lends support from a
recent human challenge study demonstrating that indeed,
serotype-specific blood memory B-cells correlated with nasopha-
ryngeal carriage, while circulating serotype-specific IgG or IgA
levels or even functional capacity of serum antibody were not asso-
ciated with protection against carriage [36]. In this case, we can
speculate that PCV7 sufficiently stimulated specific memory B cells
after 3 doses to protect against nasopharyngeal carriage acquisi-
tion of vaccine-serotype pneumococcus. Adding booster at 12
months of age, although resulting in boosting circulating antibody
concentration, was not needed in the presence of the critical num-
ber of memory B cells. In our study, the protection against carriage
without the booster was similar to that of the booster up to age 30
R. Dagan et al. / Vaccine 36 (2018) 2774–2782 2781months, and we did not examine further durations of protection. It
is thus not clear whether the booster dose further stimulated the
memory B-cell potentially resulting in longer protection than with-
out a booster. This necessitates a longer follow-up, with additional
studies needed measuring both B cell memory and antibodies con-
centration in correlation to protection against carriage for longer
durations.
Other than the differences in the immunogenicity of the 3+1
and 3+0 schedules, one additional major concern regarding the
use of reduced schedules is the possibility of lower indirect (herd)
protection, as was observed in Australia compared to the United
Kingdom and the United States, following PCV13 implementation
[22]. The study raised questions about the serotypes included
PCV13 beyond those in PCV7 and whether the longevity of protec-
tion against carriage of the additional PCV13 serotypes could not
be shorter than that of the PCV7 serotypes. Since the key for suc-
cessful herd protection is the reduction of new carriage acquisition,
the question raised by the Australian experience emphasized that
choosing 3+0 over 3+1 schedule should be accompanied with strict
monitoring of pneumococcal disease rates in both vaccinated and
non-vaccinated populations (both children >5 years and adults).
Indeed, a transient increase in non-PCV7 serotypes carriage rate
was observed in our study in the 3+0 vs. the 0+2 schedules (but
not when the 3+1 and the 0+2 schedules were compared), again
emphasizing the importance of strict monitoring when choosing
3+0 over 3+1 schedule.
The data from our controls (the 0+2 schedule) are important. In
the 0+2 group, antibodies concentration and carriage acquisition
rates were favorable with the 3+1 and the 3+0 groups, when eval-
uated in the 2nd and the 3rd years of life. However, in the 0+2
schedule, infants (<12 months) are not directly protected against
vaccine-type acquisition of carriage. This point is important in
view of recent thought to potentially implement regimens with
only 1 dose in infancy and a second later in life (booster at 9
months of age), relying on herd protection derived from reduction
of cases.
The main strengths of our study include the relatively large
number of subjects, the methodology of randomized, controlled
trial and the fact that the study was conducted in the pre-PCV
licensure era. Additionally, the relatively long-term follow-up for
carriage enabled appreciation of the efficacy up to 2.5 years post
the last dose of the 3+0 regimen.
The main limitation of the current study is that only PCV7+6A
serotypes were evaluated (rather than PCV13 or PCV10 serotypes,
currently in use).
In conclusion, while a toddler booster PCV7 dose increased anti-
body concentrations, in the currently tested regimen of 2, 4 and 6
months, the added benefit of the booster dose to reduce carriage of
PCV7+6A serotypes was not shown. This suggests that protection
against nasopharyngeal acquisition of S. pneumoniae does not nec-
essarily depend on circulating IgG, but may also depend on other
factors, such as the presence of circulating or submucosal memory
B-cells.Source of support
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